Literature DB >> 9744339

Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.

M Filesi1, A Signore, G Ventroni, F F Melacrinis, G Ronga.   

Abstract

UNLABELLED: We evaluated the role of first (131)I-whole-body scan and of first serum thyroglobulin (Tg) measurement after surgery in the early diagnosis of metastases from differentiated thyroid carcinoma (DTC).
METHODS: In 269 patients with metastases from DTC, we retrospectively evaluated the results of first whole-body scan (performed 40 days after surgery with diagnostic or therapeutic (131)I dose) and in 69 of them we also evaluated the result of first Tg measurement (performed the day before the first whole-body scan) in relation to the presence, localization and type of metastases.
RESULTS: In all patients, the first whole-body scan was positive for the thyroid remnant, and in 54.3% of patients it was also positive for metastases. In the remaining 45.7% of patients, metastases were detected during the follow-up. First Tg levels were >60 ng/ml in 66.7% of patients with metastases. First whole-body scan detected metastases in 47.8% of patients with Tg values <60 ng/ml, while Tg values were >60 ng/ml in 61.3% of patients with first whole-body scan negative for metastases. The combined results of both first whole-body scan and first Tg measurement allowed the early detection of metastases in 82.6% of patients. Whole-body scan detected distant metastases more frequently than local lymph node metastases (p < 0.01).
CONCLUSION: In more than 80% of patients, metastases were suspected or diagnosed as early as 40 days after surgery in the presence of residual thyroid tissue by combined evaluation of results of first whole-body scan and Tg measurement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744339

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.

Authors:  Fabio Pomerri; Anna Rita Cervino; Faise Al Bunni; Laura Evangelista; Pier Carlo Muzzio
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

2.  Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Authors:  Valentina Zilioli; Alessia Peli; Maria Beatrice Panarotto; Giancarlo Magri; Ahmed Alkraisheh; Christiane Wiefels; Carlo Rodella; Raffaele Giubbini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

3.  Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.

Authors:  Marie-Odile Bernier; Olivier Morel; Patrice Rodien; Jean-Pierre Muratet; Philippe Giraud; Vincent Rohmer; Christian Jeanguillaume; Jean-Claude Bigorgne; Pierre Jallet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

4.  Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer.

Authors:  Do-Hoon Kim; Ji-Hoon Jung; Seung Hyun Son; Choon-Young Kim; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2013-10-15

5.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 6.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

7.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

8.  Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.

Authors:  Lutz S Freudenberg; Walter Jentzen; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 10.057

9.  Clinical use of PET/CT in thyroid cancer diagnosis and management.

Authors:  Fx Sundram
Journal:  Biomed Imaging Interv J       Date:  2006-10-01

10.  Current role of radionuclide imaging in differentiated thyroid cancer.

Authors:  K T Wong; Frankie P T Choi; Yolanda Y P Lee; Anil T Ahuja
Journal:  Cancer Imaging       Date:  2008-09-10       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.